Acorda Therapeutics, Inc.
ACORQ
OTC PK
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 20.29M | 37.99M | 27.72M | 29.68M | 22.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.29M | 37.99M | 27.72M | 29.68M | 22.26M |
| Cost of Revenue | 4.66M | 6.61M | 4.59M | 4.62M | 4.62M |
| Gross Profit | 15.63M | 31.38M | 23.12M | 25.06M | 17.64M |
| SG&A Expenses | 28.37M | 22.21M | 23.15M | 21.83M | 22.51M |
| Depreciation & Amortization | 644.00K | 7.69M | 7.69M | 7.69M | 7.69M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.68M | 36.50M | 35.44M | 34.13M | 34.83M |
| Operating Income | -13.39M | 1.48M | -7.72M | -4.46M | -12.57M |
| Income Before Tax | -27.28M | -255.87M | -9.94M | -11.35M | -18.86M |
| Income Tax Expenses | 114.00K | -38.11M | -1.06M | -1.97M | -2.04M |
| Earnings from Continuing Operations | -27.40M | -217.76M | -8.89M | -9.38M | -16.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.40M | -217.76M | -8.89M | -9.38M | -16.82M |
| EBIT | -13.39M | 1.48M | -7.72M | -4.46M | -12.57M |
| EBITDA | -12.51M | 9.40M | 195.00K | 3.46M | -4.65M |
| EPS Basic | -22.06 | -175.33 | -7.16 | -7.55 | -13.55 |
| Normalized Basic EPS | -10.59 | -3.64 | -7.62 | -6.12 | -10.04 |
| EPS Diluted | -22.06 | -175.33 | -7.16 | -7.55 | -13.55 |
| Normalized Diluted EPS | -10.59 | -3.64 | -7.62 | -6.12 | -10.04 |
| Average Basic Shares Outstanding | 1.24M | 1.24M | 1.24M | 1.24M | 1.24M |
| Average Diluted Shares Outstanding | 1.24M | 1.24M | 1.24M | 1.24M | 1.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
